AtomVie

Samsung BiologicsBiotechSouth Korea

62% match

Samsung Biologics operates as a global contract development and manufacturing organization (CDMO) providing end-to-end biopharmaceutical services to pharmaceutical and biotech companies. The company offers a range of services including cell line development, process development, analytical testing, drug substance and drug product manufacturing, and advanced modalities like bioconjugation and mRNA.

SINOTHERAPEUTICS INC.688247 · PharmaceuticalsChina

62% matchPublic

Sinotherapeutics Inc. is a high-tech pharmaceutical enterprise focused on the research, commercial production, and sales of advanced drug formulations, including anti-infective, anti-tumor, metabolic, and cardiovascular medications. The company also provides innovative drug formulation CRO and CMO services to global patients and pharmaceutical partners.

GNI Group Ltd.BiotechnologyJapan

61% match

GNI Group Ltd. is a global healthcare company headquartered in Tokyo, Japan, that engages in the entire pharmaceutical value chain ranging from drug discovery to manufacturing.

CambrexPharmaceuticalsUnited States

61% match

Cambrex Corporation is a contract development and manufacturing organization (CDMO) with a corporate headquarters in East Rutherford, New Jersey, USA. The company operates multiple facilities across North America and Europe to support the pharmaceutical industry.

AGC BiologicsBiotechUnited States

61% match

AGC Biologics is a global contract development and manufacturing organization (CDMO) that provides services for protein-based biologics and advanced therapies, including mammalian and microbial production, viral vectors, cell therapy, plasmid DNA, and mRNA. The company supports biopharmaceutical developers by offering process development, analytical formulation, cGMP manufacturing, and fill-finish services to help bring life-changing treatments to market.

PolyPeptide Group AG0AAJ · PharmaceuticalsBaar, Switzerland

61% matchPublicAI 0/100Green 6/100

Operating globally, PolyPeptide Group AG functions as a prominent contract development and manufacturing organization (CDMO). The company specializes in producing both proprietary and generic GMP-certified peptides, which are supplied to pharmaceutical and biotechnology firms. These crucial components are integrated into approved pharmaceutical products, drugs in various stages of clinical development, and generic medications. PolyPeptide Group also handles the manufacturing of bespoke research-grade peptides and is engaged in the development of neoantigen peptides designed to advance personalized cancer therapies. Its services further encompass the production of peptides for commercially available peptide therapeutics, as well as the creation of peptide-based generics for both human and animal health sectors, alongside peptides for the cosmetics industry. Additionally, the company offers vital regulatory affairs assistance. Established in 1952, PolyPeptide Group AG maintains its corporate headquarters in Zug, Switzerland, and operates as a subsidiary of Draupnir Holding B.V.